ACB
Price
$5.08
Change
-$0.31 (-5.75%)
Updated
Aug 15 closing price
Capitalization
286.3M
81 days until earnings call
TLRY
Price
$1.03
Change
-$0.15 (-12.71%)
Updated
Aug 15 closing price
Capitalization
1.13B
46 days until earnings call
Interact to see
Advertisement

ACB vs TLRY

Header iconACB vs TLRY Comparison
Open Charts ACB vs TLRYBanner chart's image
Aurora Cannabis
Price$5.08
Change-$0.31 (-5.75%)
Volume$1.61M
Capitalization286.3M
Tilray Brands
Price$1.03
Change-$0.15 (-12.71%)
Volume$90.05M
Capitalization1.13B
ACB vs TLRY Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. TLRY commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (ACB: $5.39 vs. TLRY: $1.18)
Brand notoriety: ACB and TLRY are both notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 121% vs. TLRY: 293%
Market capitalization -- ACB: $286.3M vs. TLRY: $1.13B
ACB [@Pharmaceuticals: Generic] is valued at $286.3M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.13B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACB and TLRY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 5 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • ACB’s TA Score: 5 bullish, 4 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ACB is a better buy in the short-term than TLRY.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а +28.03% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was +81.40% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.13B) has a higher market cap than ACB($286M). ACB YTD gains are higher at: 26.824 vs. TLRY (-22.556). ACB has higher annual earnings (EBITDA): 50.2M vs. TLRY (-2.13B). TLRY has more cash in the bank: 256M vs. ACB (109M). ACB has less debt than TLRY: ACB (101M) vs TLRY (329M). TLRY has higher revenues than ACB: TLRY (821M) vs ACB (321M).
ACBTLRYACB / TLRY
Capitalization286M1.13B25%
EBITDA50.2M-2.13B-2%
Gain YTD26.824-22.556-119%
P/E Ratio21.12N/A-
Revenue321M821M39%
Total Cash109M256M43%
Total Debt101M329M31%
FUNDAMENTALS RATINGS
ACB vs TLRY: Fundamental Ratings
ACB
TLRY
OUTLOOK RATING
1..100
8322
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9198
PRICE GROWTH RATING
1..100
4935
P/E GROWTH RATING
1..100
8494
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (52) in the Biotechnology industry is in the same range as ACB (59) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to ACB’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to ACB’s over the last 12 months.

ACB's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as TLRY (98) in the Biotechnology industry. This means that ACB’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's Price Growth Rating (35) in the Biotechnology industry is in the same range as ACB (49) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to ACB’s over the last 12 months.

ACB's P/E Growth Rating (84) in the Pharmaceuticals Other industry is in the same range as TLRY (94) in the Biotechnology industry. This means that ACB’s stock grew similarly to TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBTLRY
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 16 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PBCRF0.47N/A
N/A
PT Bank Central Asia
TDCB8.90N/A
N/A
Third Century Bancorp
CSPHF0.86N/A
N/A
CSTONE PHARMACEUTICALS
ISMAY20.44-0.31
-1.52%
Indra Sistemas SA
PYYX4.20-0.10
-2.33%
Pyxus International, Inc.

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with CGC. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
-2.53%
CGC - ACB
64%
Loosely correlated
-9.15%
OGI - ACB
59%
Loosely correlated
-2.50%
CRON - ACB
56%
Loosely correlated
-3.82%
TLRY - ACB
53%
Loosely correlated
-5.60%
CRDL - ACB
33%
Loosely correlated
+20.72%
More

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been loosely correlated with CGC. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if TLRY jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
-12.71%
CGC - TLRY
61%
Loosely correlated
-12.75%
CRON - TLRY
61%
Loosely correlated
-5.95%
OGI - TLRY
57%
Loosely correlated
-8.33%
VTRS - TLRY
34%
Loosely correlated
-0.75%
ELAN - TLRY
33%
Loosely correlated
-0.22%
More